NCT02094560View on ClinicalTrials.gov

CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors

PHASE2TerminatedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 8, 2011

Primary Completion Date

September 8, 2015

Study Completion Date

April 10, 2017

Conditions
Advanced Endstage Solid Carcinomas in Adults
Interventions
DRUG

CAP7.1

CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase

Trial Locations (1)

10117

Charite, University Hospital, Berlin

Sponsors

Collaborators (1)

Mundipharma-EDO GmbH
All Listed Sponsors
collaborator

Mundipharma-EDO GmbH

INDUSTRY

lead

CellAct Pharma GmbH

INDUSTRY